162 related articles for article (PubMed ID: 35732097)
21. Regulatory T cell heterogeneity and therapy in autoimmune diseases.
Zhang R; Miao J; Zhu P
Autoimmun Rev; 2021 May; 20(5):102715. PubMed ID: 33197573
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
[TBL] [Abstract][Full Text] [Related]
23. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context.
Baeyens A; Saadoun D; Billiard F; Rouers A; Grégoire S; Zaragoza B; Grinberg-Bleyer Y; Marodon G; Piaggio E; Salomon BL
J Immunol; 2015 Feb; 194(3):999-1010. PubMed ID: 25548233
[TBL] [Abstract][Full Text] [Related]
24. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
25. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
[TBL] [Abstract][Full Text] [Related]
26. Engineering IL-2 for immunotherapy of autoimmunity and cancer.
Hernandez R; Põder J; LaPorte KM; Malek TR
Nat Rev Immunol; 2022 Oct; 22(10):614-628. PubMed ID: 35217787
[TBL] [Abstract][Full Text] [Related]
27. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
28. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Sharma M; Khong H; Fa'ak F; Bentebibel SE; Janssen LME; Chesson BC; Creasy CA; Forget MA; Kahn LMS; Pazdrak B; Karki B; Hailemichael Y; Singh M; Vianden C; Vennam S; Bharadwaj U; Tweardy DJ; Haymaker C; Bernatchez C; Huang S; Rajapakshe K; Coarfa C; Hurwitz ME; Sznol M; Hwu P; Hoch U; Addepalli M; Charych DH; Zalevsky J; Diab A; Overwijk WW
Nat Commun; 2020 Jan; 11(1):661. PubMed ID: 32005826
[TBL] [Abstract][Full Text] [Related]
29. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
[TBL] [Abstract][Full Text] [Related]
30. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.
Klatzmann D; Abbas AK
Nat Rev Immunol; 2015 May; 15(5):283-94. PubMed ID: 25882245
[TBL] [Abstract][Full Text] [Related]
31. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.
Spangler JB; Tomala J; Luca VC; Jude KM; Dong S; Ring AM; Votavova P; Pepper M; Kovar M; Garcia KC
Immunity; 2015 May; 42(5):815-25. PubMed ID: 25992858
[TBL] [Abstract][Full Text] [Related]
32. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity.
Zhou P
Cytokine Growth Factor Rev; 2022 Oct; 67():80-88. PubMed ID: 35803833
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
Dannull J; Su Z; Rizzieri D; Yang BK; Coleman D; Yancey D; Zhang A; Dahm P; Chao N; Gilboa E; Vieweg J
J Clin Invest; 2005 Dec; 115(12):3623-33. PubMed ID: 16308572
[TBL] [Abstract][Full Text] [Related]
34. Modulation of T cell responses by IL-2 and IL-2 complexes.
Boyman O; Kolios AG; Raeber ME
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S54-7. PubMed ID: 26457438
[TBL] [Abstract][Full Text] [Related]
35. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
36. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
Kosmaczewska A
Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
[TBL] [Abstract][Full Text] [Related]
37. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.
Ballesteros-Tato A
Immunotherapy; 2014; 6(11):1207-20. PubMed ID: 25496335
[TBL] [Abstract][Full Text] [Related]
38. Engineering IL-2 to Give New Life to T Cell Immunotherapy.
Overwijk WW; Tagliaferri MA; Zalevsky J
Annu Rev Med; 2021 Jan; 72():281-311. PubMed ID: 33158368
[TBL] [Abstract][Full Text] [Related]
39. IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA; Buckner JH; Greenbaum CJ
Clin Immunol; 2013 Dec; 149(3):324-31. PubMed ID: 23499139
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-2 and autoimmune disease occurrence and therapy.
Geng X; Zhang R; Yang G; Jiang W; Xu C
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(11):1462-7. PubMed ID: 23111957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
